BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 20142539)

  • 1. Immunohistochemical studies of conjunctival nevi and melanomas.
    Jakobiec FA; Bhat P; Colby KA
    Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical studies of atypical conjunctival melanocytic nevi.
    Jakobiec FA; Colby K; Bajart AM; Saragas SJ; Moulin A
    Arch Ophthalmol; 2009 Aug; 127(8):970-80. PubMed ID: 19667333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva].
    Steuhl KP; Rohrbach JM; Knorr M
    Klin Monbl Augenheilkd; 1991 Sep; 199(3):187-91. PubMed ID: 1753671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
    Furusato E; Hidayat AA; Man YG; Auerbach A; Furusato B; Rushing EJ
    Arch Ophthalmol; 2009 Aug; 127(8):964-9. PubMed ID: 19667332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors.
    Steuhl KP; Rohrbach JM; Knorr M; Thiel HJ
    Ophthalmology; 1993 Feb; 100(2):208-15. PubMed ID: 8437829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45.
    Heegaard S; Jensen OA; Prause JU
    Melanoma Res; 2000 Aug; 10(4):350-4. PubMed ID: 10985669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunohistochemical markers for cytoplasmic antigens in acquired melanosis, malignant melanomas, and nevi of the conjunctiva].
    Hitzer S; Bialasiewicz AA; Richard G
    Klin Monbl Augenheilkd; 1998 Oct; 213(4):230-7. PubMed ID: 9848068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
    Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
    Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
    Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
    Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p16ink4a expression in benign and malignant melanocytic conjunctival lesions.
    Zoroquiain P; Fernandes BF; González S; Novais GN; Schalper KA; Burnier MN
    Int J Surg Pathol; 2012 Jun; 20(3):240-5. PubMed ID: 22287653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67.
    Milman T; Zhang Q; Ang S; Elder D; Ida CM; Salomao DR; Lally SE; Shields JA; Hamershock RA; Sioufi K; Shields CL; Eagle RC
    Hum Pathol; 2020 Sep; 103():107-119. PubMed ID: 32707054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMB-45 immunohistochemical staining of conjunctival melanocytic lesions.
    McDonnell JM; Sun YY; Wagner D
    Ophthalmology; 1991 Apr; 98(4):453-8. PubMed ID: 1711186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMB-45 antibody reactivity in pigmented lesions of the conjunctiva.
    Glasgow BJ; McCall LC; Foos RY
    Am J Ophthalmol; 1990 Jun; 109(6):696-700. PubMed ID: 2189315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative immunoreactivity of CD-68 and HMB-45 in malignant melanoma, neural tumors and nevi.
    Shah IA; Gani OS; Wheler L
    Pathol Res Pract; 1997; 193(7):497-502. PubMed ID: 9342756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent melanocytic nevus: a histologic and immunohistochemical evaluation.
    Hoang MP; Prieto VG; Burchette JL; Shea CR
    J Cutan Pathol; 2001 Sep; 28(8):400-6. PubMed ID: 11493377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical profiling including beta-catenin in conjunctival melanocytic lesions.
    Reddy HS; Keene CD; Chang SH; Jian-Amadi A; Cimino PJ
    Exp Mol Pathol; 2017 Apr; 102(2):198-202. PubMed ID: 28161440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas.
    Yu CH; Chen HH; Liu CM; Jeng YM; Wang JT; Wang YP; Liu BY; Sun A; Chiang CP
    J Oral Pathol Med; 2005 Oct; 34(9):540-5. PubMed ID: 16138892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo confocal microscopy of pigmented conjunctival tumors.
    Messmer EM; Mackert MJ; Zapp DM; Kampik A
    Graefes Arch Clin Exp Ophthalmol; 2006 Nov; 244(11):1437-45. PubMed ID: 16598465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis.
    LeBlanc RE; Miller DM; Zegans ME
    J Cutan Pathol; 2021 Dec; 48(12):1442-1448. PubMed ID: 34089198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.